Wild-type IDH2 is a therapeutic target for triple-negative breast cancer.
Li JJ, Yu T, Zeng P, Tian J, Liu P, Qiao S, Wen S, Hu Y, Liu Q, Lu W, Zhang H, Huang P.
Li JJ, et al. Among authors: lu w.
Nat Commun. 2024 Apr 24;15(1):3445. doi: 10.1038/s41467-024-47536-6.
Nat Commun. 2024.
PMID: 38658533